

APC anti-human CD95 (Fas) Antibody

| | |
|--------------------------|--|
| Catalog# / Size | 305611 / 25 tests 305612 / 100 tests |
| Clone | DX2 |
| Regulatory Status | RUO |
| Workshop | VI C-64 |
| Other Names | Fas, APO-1, TNFRSF6 |
| Isotype | Mouse IgG1, κ |
| Description | CD95 is a 45 kD single chain type I glycoprotein also known as Fas, APO-1, and TNFRSF6. It is a member of the TNF receptor superfamily. CD95 is expressed on T and B lymphocytes, monocytes, neutrophils, and fibroblasts. CD95 expression is upregulated by activation. The extracellular region of CD95 binds to CD178 (Fas ligand). CD178 binding to CD95 induces apoptosis and has been shown to play a role in the maintenance of peripheral tolerance. |

Product Details

| | |
|---|---|
| Verified Reactivity | Human, Cynomolgus, Rhesus |
| Reported Reactivity | African Green, Baboon, Capuchin Monkey, Chimpanzee, Common Marmoset, Cotton-topped Tamarin, Pigtailed Macaque, Sooty Mangabey |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Immunogen | CD95 transfected L cells |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA) |
| Preparation | The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. |
| Concentration | Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.) |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. |
| Excitation Laser | Red Laser (633 nm) |
| Application Notes | The DX2 antibody is useful for inducing apoptosis of Fas-positive cells. Additional reported applications (for the relevant formats) include: <i>in vitro</i> induction of apoptosis ³ (DX2 antibody is required to be cross-linked for effective induction of apoptosis) and immunohistochemical staining ^{4,5} of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 305655 and 305656). Note: EOS9.1 antibody can induce apoptosis without cross-linking. |
| Application References | <ol style="list-style-type: none"> Schlossman S, <i>et al.</i> Eds.1995. Leucocyte Typing V. Oxford University Press. New York. Kishimoto T, <i>et al.</i> Eds. 1997. Leucocyte Typing VI. Garland Publishing Inc. New York. Cifone M, <i>et al.</i> 1994. <i>J. Exp. Med.</i> 180:1547. (Apop) Zietz C, <i>et al.</i> 2001. <i>Am. J. Pathol.</i> 159:963. (IHC) Sergi C, <i>et al.</i> 2000. <i>Am. J. Pathol.</i> 156:1589. (IHC) |
| (PubMed link indicates BioLegend citation) | |

6. Xie S, *et al.* 2010. *J. Immunol.* 184:2289. (FC) [PubMed](#)
7. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
8. Sestak K, *et al.* 2007. *Vet. Immunol. Immunopathol.* 119:21.
9. Rout N, *et al.* 2010. *PLoS One* 5:e9787. (FC)
10. Dixit N, *et al.* 2012. *J. Immunol.* 189:5954. [PubMed](#)

Product Citations

1. Sulejmani O, *et al.* 2021. *Cancers (Basel)*. 13:. [PubMed](#)
2. Cao B, *et al.* 2022. *Nat Commun.* 13:6203. [PubMed](#)
3. Wang Y, *et al.* 2014. *J Endocrinol.* 222:151. [PubMed](#)
4. Paschal A, *et al.* 2015. *J Immunol.* 195: 1868-1882. [PubMed](#)
5. He P, *et al.* 2020. *Front Oncol.* 1.351388889. [PubMed](#)
6. Jeong D, *et al.* 2021. *eLife.* 0.416666666666667. [PubMed](#)
7. de Jonge K *et al.* 2019. *Scientific reports.* 9(1):4487 . [PubMed](#)
8. Cohen G 2013. *J Immunol.* 190:5237. [PubMed](#)
9. Backes CS, *et al.* 2018. *J Biol Chem.* 293:16348. [PubMed](#)
10. Toews K, *et al.* 2020. *Mol Carcinog.* 724:59. [PubMed](#)
11. Alter G, *et al.* 2020. *Cell.* 183(1):185-196.e14. [PubMed](#)
12. Kulshrestha A, *et al.* 2019. *J Oncol.* 2019:2343876. [PubMed](#)
13. Aldeghaither DS, *et al.* 2019. *Cancer Immunol Res.* 7:230. [PubMed](#)
14. Hu X, *et al.* 2016. *PLoS One.* 11: 0152368. [PubMed](#)
15. Perdigoto AL, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
16. Wang D, *et al.* 2022. *EMBO Rep.* 23:e53691. [PubMed](#)
17. Chen Y, *et al.* 2020. *Cell.* 1496:183. [PubMed](#)
18. Fu Y, *et al.* 2021. *Cell Reports.* 36(2):109344. [PubMed](#)
19. Chang XL, *et al.* 2021. *Nat Commun.* 12:3343. [PubMed](#)
20. Aalam F, *et al.* 2020. *PLoS Pathog.* 16:e1008968. [PubMed](#)

RRID AB_314549 (BioLegend Cat. No. 305611)
 AB_314550 (BioLegend Cat. No. 305612)

Antigen Details

| | |
|---------------------------|--|
| Structure | TNFR superfamily, type I transmembrane protein, 45 kD |
| Distribution | T cells and B cells, monocytes, neutrophils, fibroblasts, expression level upregulated on activated lymphocytes |
| Function | Mediates apoptosis |
| Ligand/Receptor | Fas ligand (CD178) |
| Cell Type | B cells, Fibroblasts, Lymphocytes, Monocytes, Neutrophils, T cells |
| Biology Area | Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Immunology, Neuroscience |
| Molecular Family | CD Molecules |
| Antigen References | 1. Krammer P, <i>et al.</i> 1994. <i>Immunol. Rev.</i> 142:175. 2. Nagata S, <i>et al.</i> 1995. <i>Science</i> 267:1449. |
| Gene ID | 355 |


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-human CD95 (Fas), Biotin anti-human CD95 (Fas), FITC anti-human CD95 (Fas), PE anti-human CD95 (Fas), PE/Cyanine5 anti-human CD95 (Fas), Purified anti-human CD95 (Fas), Alexa Fluor® 488 anti-human CD95 (Fas), Alexa Fluor® 647 anti-human CD95 (Fas), Brilliant Violet 421™ anti-human CD95 (Fas), Pacific Blue™ anti-human CD95 (Fas), PE/Cyanine7 anti-human CD95 (Fas), Brilliant Violet 605™ anti-human CD95 (Fas), PerCP/Cyanine5.5 anti-human CD95 (Fas), Purified anti-human CD95 (Fas) (Maxpar® Ready), PE/Dazzle™ 594 anti-human CD95 (Fas), APC/Fire™ 750 anti-human CD95 (Fas), APC/Cyanine7 anti-human CD95 (Fas), Brilliant Violet 510™ anti-human CD95 (Fas), Brilliant Violet 711™ anti-human CD95 (Fas), Brilliant Violet 785™ anti-human CD95 (Fas), Brilliant Violet 650™ anti-human CD95 (Fas), Alexa Fluor® 700 anti-human CD95 (Fas), TotalSeq™-A0156 anti-human CD95 (Fas), TotalSeq™-C0156 anti-human CD95 (Fas), TotalSeq™-B0156 anti-human CD95 (Fas), Ultra-LEAF™ Purified anti-human CD95 (Fas), TotalSeq™-D0156 anti-human CD95 (Fas), PE/Fire™ 640 anti-human CD95 (Fas),

Product Data



Human peripheral blood lymphocytes
stained with DX2 APC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587